Skip to main content

Advertisement

Table 4 The extracted antidiabetic medication prescription data obtained in the retrospective cohort study

From: Changes in antidiabetic prescription patterns and indicators of diabetic control among 200,000 patients over 13 years at a single institution in Japan

Year 2001 2005 2010 2013 rs# p value#
n 170 170 170 170   
Sulfonylureas (%) 78 (46) 63 (37) 67 (39) 59 (35)   0.02*
Glimepiride (n) 12 31 54 47   
Glimepiridea (mg) 3 (2, 5.625) [1, 6] 3 (2, 4) [1, 6] 1.875 (1, 3) [0.5, 6] 1 (0.5, 2) [0.5, 6] −0.45 <0.01
Biguanide (%) 78 (46) 83 (49) 84 (49) 76 (45)   0.76*
Metformin (n) 77 83 84 76   
Metformina (mg) 750 (750, 750) [375, 750] 750 (750, 750) [250, 750] 750 (750, 750) [250, 1000] 750 (750, 1500) [250, 2250] 0.28 <0.01
Thiazolidine (%) 5 (3) 35 (21) 83 (49) 48 (28)   <0.01*
Pioglitazonea (mg) 30 (30, 30) [30] 15 (15, 30) [7.5, 30] 15 (15, 30) [7.5, 45] 15 (15, 30) [7.5, 45] 0.06 0.16
α-GI (%) 54 (32) 56 (33) 60 (35) 43 (25)   0.30*
Voglibose (n) 43 50 52 37   
Voglibosea (mg) 0.9 (0.6, 0.9) [0.4, 0.9] 0.6 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.2, 0.9] 0.9 (0.6, 0.9) [0.3, 0.9] 0.26 <0.01
Meglitinides (%) 12 (7) 15 (9) 22 (13) 8 (5)   0.44*
Nateglinide (n) 12 15 19 6   
Nateglinidea (mg) 270 (270, 270) [270, 270] 270 (270, 270) [60, 270] 270 (180, 270) [60, 360] 135 (90, 225) [90, 360] −0.18 0.01
DPP4I (%) 0 (0) 0 (0) 1 (1) 70 (41)   <0.01*
Sitagliptin (n) 0 0 1 52   
Sitagliptina (mg)    50 (50, 50) [50, 50] 50 (25, 50) [25, 100] 0.09 0.30
Insulins (%) 69 (41) 96 (57) 97 (57) 93 (55)   <0.01*
  1. Median (interquartile range) [range] or n (%)
  2. α-GI α-glucosidase inhibitors, DPP4I dipeptidyl peptidase-4 inhibitors
  3. # Analysis results over 13 years; Additional file 4 shows this in detail
  4. * According to the Cochran-Armitage trend test
  5. aYearly median daily dose for each patient